ABBVIE
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel for the Improvement of Skin Quality in Adult Participants
- Conditions
- Skin Quality Deficit
- Interventions
- Device: ELAPR002f Injectable Gel
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT06151535
- Locations
- ๐ฎ๐น
CRC - Centro Ricerche Cliniche di Verona S.r.l. /ID# 226370, Verona, Italy
Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy
- Conditions
- Spasticity
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 107
- Registration Number
- NCT06150729
- Locations
- ๐ฒ๐ฝ
Hospital General ISSSTE Tacuba /ID# 261460, Ciudad de Mรฉxico, Ciudad De Mexico, Mexico
๐ฒ๐ฝCri Dif Jalisco /Id# 261459, Guadalajara, Mexico
๐ฒ๐ฝHospital General Regional 180 IMSS /ID# 261458, Guadalajara, Jalisco, Mexico
A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 41
- Registration Number
- NCT06148181
- Locations
- ๐บ๐ธ
Acpru /Id# 261162, Grayslake, Illinois, United States
A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants
- Conditions
- Masseter Muscle Prominence
- Interventions
- Drug: Placebo for BOTOX
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 259
- Registration Number
- NCT06137287
- Locations
- ๐ฏ๐ต
Kotoni Tower Skin And Cosmetic Surgery Clinic /ID# 260668, Sapporo, Hokkaido, Japan
๐ฏ๐ตTokai University Hospital /ID# 254204, Isehara, Kanagawa, Japan
๐ฏ๐ตJun Clinic /Id# 254870, Nagano, Fukui, Japan
An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in Adult Participants in the United Kingdom (UK)
- Conditions
- Crohn's Disease
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 53
- Registration Number
- NCT06126146
- Locations
- ๐ฌ๐ง
Guys and St Thomas NHS Foundation Trust /ID# 258986, London, London, City Of, United Kingdom
๐ฌ๐งNHS Lothian /ID# 260901, Edinburgh, United Kingdom
๐ฌ๐งThe Royal London Hospital /ID# 259047, London, United Kingdom
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 132
- Registration Number
- NCT06125795
- Locations
- ๐ช๐ธ
Hospital Jerez De La Frontera /ID# 258282, Jerez de la Frontera, Cadiz, Spain
๐ช๐ธHospital Universitario Reina Sofia /ID# 271507, Cรณrdoba, Cordoba, Spain
๐ช๐ธHospital Lucus Augusti /ID# 271542, Lugo, Spain
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
- Conditions
- Vitiligo
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 614
- Registration Number
- NCT06118411
- Locations
- ๐บ๐ธ
Joseph Raoof Md,Inc /Id# 260055, Encino, California, United States
๐บ๐ธAlliance Dermatology and Mohs Center /ID# 259926, Phoenix, Arizona, United States
๐บ๐ธUniversity of California Irvine /ID# 260080, Irvine, California, United States
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 660
- Registration Number
- NCT06109272
- Locations
- ๐ซ๐ท
Hopital Beaujon /ID# 256551, Clichy, Ile-de-France, France
๐ซ๐ทCHU Grenoble - Hopital Michallon /ID# 256627, La Tronche, Isere, France
๐บ๐ธCity of Hope /ID# 261468, Duarte, California, United States
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
- Conditions
- Parkinson's Disease (PD)
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 450
- Registration Number
- NCT06107426
- Locations
- ๐บ๐ธ
Parkinson's Disease and Movement Disorders Center /ID# 264703, Palo Alto, California, United States
๐บ๐ธParkinson's Disease and Movement Disorders Center of Boca Raton /ID# 253465, Boca Raton, Florida, United States
๐บ๐ธUniversity of South Florida- Neuroscience Institute /ID# 253470, Tampa, Florida, United States
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
- Conditions
- Unresectable Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 280
- Registration Number
- NCT06107413
- Locations
- ๐บ๐ธ
Mayo Clinic Arizona /ID# 262610, Phoenix, Arizona, United States
๐บ๐ธHighlands Oncology Group, PA /ID# 259424, Springdale, Arkansas, United States
๐บ๐ธCity of Hope National Medical Center /ID# 257576, Duarte, California, United States